Here’s a shocking fact: Cervical cancer is the fastest-growing cancer in Canada, yet it’s nearly 100% preventable. So why are we falling behind? Advocates, doctors, and health groups are sounding the alarm, demanding urgent action from the federal government to ramp up screening, prevention, and vaccination efforts. But here’s where it gets controversial: despite having a highly effective HPV vaccine available for years, Canada’s vaccination rates are alarmingly low, and access to the vaccine remains uneven across the country. Could this be a matter of policy gaps, public awareness, or something else entirely?
On Wednesday, the Society of Gynecologic Oncology of Canada, the Women’s Health Coalition, and 19 other organizations gathered in Ottawa to urge lawmakers to address this growing crisis. Dr. Shannon Salvador, president of the Society of Gynecologic Oncology of Canada, highlighted a bold goal: eliminate cervical cancer by 2040. Countries like Australia and Sweden are already on the brink of achieving this, with fewer than four cases per 100,000 people. But Canada’s rate is more than double that—and rising. “This is a national health crisis,” Dr. Salvador emphasized.
The human papillomavirus (HPV) is the culprit behind over 90% of cervical cancers. It’s a common virus with multiple strains, and about 75% of people will encounter it at least once in their lifetime. The good news? The HPV vaccine is a game-changer, proven to prevent up to 90% of HPV-related cancers. A 2014-2018 study across 14 countries, including Canada, found that vaccinated girls saw an 83% reduction in the two most dangerous HPV strains. And this is the part most people miss: HPV doesn’t just cause cervical cancer—it’s also linked to cancers of the vagina, vulva, penis, anus, and mouth and throat. Yet, vaccination rates for boys remain low, even though they’re equally at risk.
Canada’s elimination goal hinges on vaccinating 90% of children under 18 by 2025. However, current vaccination rates hover around just 64%. Provincial programs target children aged 9-13, but gaps persist. Quebec leads the way, covering the vaccine for those aged 9-20 and offering a temporary program for adults up to 45. Other provinces, like B.C. and Alberta, cover costs up to age 26, while Ontario and Manitoba focus on school-aged children and high-risk groups. But with the vaccine costing $215 per dose (and adults needing two doses), affordability remains a barrier for many.
Advocates are pushing for a national catch-up program to ensure anyone under 18 can get vaccinated, regardless of whether they missed it in school. They’re also calling for publicly funded access for adults under 45. Carmen Wyton, president of the Women’s Health Coalition of Canada, is championing a Senate bill to create a national framework for women’s health. “This could standardize HPV testing and self-sampling across provinces, ensuring health equity,” Wyton said.
Some provinces, like Quebec and B.C., have already switched to HPV tests as the primary screening tool, replacing the less effective Pap test. Self-testing programs are also gaining traction. But is this enough? Critics argue that without a unified national strategy, progress will remain slow.
Here’s the burning question: Why are we still debating access to a life-saving vaccine in 2026? Is it a lack of awareness, funding, or political will? And what role should schools, parents, and healthcare providers play in closing this gap? Share your thoughts in the comments—this conversation needs your voice.
